Leadership Transition at Antag Therapeutics
Antag Therapeutics, a pioneering biopharmaceutical company focusing on obesity treatments, has announced a significant leadership transition. The company welcomes Dr. Joerg Moeller as its new Chief Executive Officer, effective immediately. This change comes as Antag Therapeutics gears up for the clinical development of its promising candidate, AT-7687, designed to tackle obesity through a novel mechanism of action.
Dr. Joerg Moeller Takes the Helm
Dr. Moeller, with over three decades of experience in the biopharmaceutical industry, brings an impressive background in leading global organizations and driving innovative strategies. Prior to joining Antag, he was the Head of Global Research and Development at Bayer AG, where he played a crucial role in overseeing the development and approval of various groundbreaking therapies. His expertise spans multiple therapeutic areas, including oncology, hematology, and infections, ensuring that he will guide Antag through its next exciting chapter.
Vision for Future Growth
As Dr. Moeller steps into his new role, he expresses enthusiasm for Antag's pioneering approach to treating obesity. His vision includes advancing the company's lead candidate, AT-7687, which enhances GLP-1 therapies while addressing tolerability issues. This innovative approach has the potential to set a new standard in obesity management, offering not just weight loss solutions but also metabolic benefits for patients.
The outgoing CEO, Dr. Alexander Sparre-Ulrich, will transition to Chief Operating Officer, continuing to support Antag's mission and helping build on the strong foundation he has laid during his tenure. Philip Just Larsen, Chair of the Board, emphasizes the company's gratitude for Dr. Sparre-Ulrich's leadership and contributions that have positioned Antag for future success.
AT-7687: A Trailblazing Therapy in Obesity Management
Antag's commitment to innovation is exemplified through its flagship candidate, AT-7687. Designed as a once-weekly subcutaneous antagonist of the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR), AT-7687 is set to begin Phase 1 clinical development soon. The therapy not only enhances weight loss but also aims to provide significant metabolic improvements for patients dealing with obesity.
Conclusion and Upcoming Events
Looking ahead, Antag Therapeutics' management team is preparing to engage with key stakeholders at J.P. Morgan’s 43rd Annual Healthcare Conference. This event will be an excellent opportunity for the team to discuss their strategic vision and ongoing developments with AT-7687. As the company moves forward with its innovative pipeline, the focus remains on addressing the pressing global challenge of obesity and its associated metabolic disorders.
Frequently Asked Questions
Who is the new CEO of Antag Therapeutics?
Dr. Joerg Moeller has been appointed as the new CEO of Antag Therapeutics.
What is the lead candidate of Antag Therapeutics?
The lead candidate is AT-7687, which targets obesity through a novel mechanism of action.
What experience does Dr. Moeller bring to his role?
Dr. Moeller has over 30 years of leadership experience in the biopharmaceutical industry, including his role at Bayer AG.
What role will Dr. Alexander Sparre-Ulrich take after his tenure as CEO?
Dr. Sparre-Ulrich will become the Chief Operating Officer and continue to support the company.
When is AT-7687 expected to enter clinical development?
AT-7687 is expected to begin Phase 1 clinical development in early 2025.
